5450 Chemin de la Côte-des-Neiges

Suite 522

Montréal, Qc

H3T 1Y6

514-282-4523

info@exactis.ca

  • White LinkedIn Icon
Send Us a Message

© 2018 by Exactis Innovation

Exactis publication highlights novel aberrations associated with clinical outcomes in ALK+ NSCLC patients on targeted therapy

July 9, 2019

Read the full article here.

Please reload